何伶利
肿瘤代谢调控与靶向治疗组
电话：021-63846590-776486
邮箱：linglihe@sjtu.edu.cn
研究方向
1. 揭示肿瘤细胞的代谢脆弱性：利用高通量筛选体系，结合相关生物学难题，鉴定和验证肿瘤细胞的代谢依赖性；并运用多组学方法解析代谢分子的调控机制。
2. 开发小分子药物：基于代谢靶点，结合前沿的药物筛选和药物设计技术，开发新型抗癌小分子，并推进临床应用。
3. 聚焦硒蛋白的生理功能和调控机制：通过建立动物疾病模型，研究硒蛋白在衰老、肥胖等慢性疾病中的功能和调控机制，以期解密硒蛋白与长寿之间的关系。
个人简历
何伶利研究员于中国科学院分子细胞科学卓越创新中心获得博士学位，师从国家高层次人才张雷研究员，聚焦Hippo信号通路在组织稳态维持和肿瘤发生发展中的功能和机制研究。随后在哈佛大学造血干细胞领域鼻祖David Scadden院士实验室从事博士后研究，专注于造血系统和血液类疾病的研究。主要方向为研究急性髓系白血病发生和耐药过程中的代谢脆弱性，并深入研究代谢相关的具体机制，聚焦于硒蛋白合成信号通路以及硒蛋白的功能研究，并利用多种创新方法进行靶向小分子药物的筛选。相关研究成果以第一作者或者共同第一作者发表在Blood, Cell Metabolism (under revision), Cancer Research, Cell Reports, eLife, Nanoscale, J Biol Chem等高质量学术期刊。何伶利多次获得哈佛大学Blavatnik Biomedical Accelerator的资助，荣获2023年国际干细胞大会（ISSCR）的Merit Award，并担任Nature Chemical Biology, Communications Biology 和Cancer Letters等多个国际学术期刊审稿人。何伶利研究员于2025年加入上海交通大学-医学院-基础医学院-生物化学与分子细胞生物学系，成立“肿瘤代谢调控与靶向治疗”课题组。
科研项目
论文与专著
1. He, L., Zhao, T., Leong, W.Z., Sharda, A., Mayerhofer, C., Mei, S., Bonilla, G.M., Menendez-Gonzalez, J.B., Gustafsson, K., Fukushima, T., et al. (2025). PSTK inhibition activates cGAS-STING, precipitating ferroptotic cell death in leukemic stem cells. Blood.
2. Zhao, T.*, He, L.*, Wong, L., Mei, S. Xu, Y., et al., and Scadden, D. T. De-repressing Nuclear Pyruvate Dehydrogenase Complex Reprograms Cancer Cells (Cell Metabolism, minor revision)
3. He, L., Yuan, L., Sun, Y., Wang, P., Zhang, H., et al., and Zhang L. (2019). Glucocorticoid Receptor Signaling Activates TEAD4 to Promote Breast Cancer Progression. Cancer Res 79, 4399-4411.
4. He, L. *, Yuan, L. *, Yu, W., Sun, Y., Jiang, D., et al. and Zhang L. (2020). A Regulation Loop between YAP and NR4A1 Balances Cell Proliferation and Apoptosis. Cell Rep 33, 108284.
5. Wang, J.*, Liu, C.*, He, L.*, Xie, Z., Bai, L., et al. and Zeng, Y. A. (2022). Selective YAP activation in Procr cells is essential for ovarian stem/progenitor expansion and epithelium repair. eLife 11.
6. Wu, M. *, Hu, L. *, He, L. *, Yuan, L., Yang, L., Zhao, B., Zhang, L., and He, X. (2024). The tumor suppressor NF2 modulates TEAD4 stability and activity in Hippo signaling via direct interaction. J Biol Chem 300.
7. He, L.#, Yu, W., Lu, Y., Zhang, W., Xu, J., and Zhang, L.# (2021). A protocol for in vivo analysis of liver tumorigenesis in mice using sleeping beauty transposon system. STAR Protocols 2, 100445.
8. He, L.#, Yu, W., Zhang, W., and Zhang, L.# (2021). An optimized two-step chromatin immunoprecipitation protocol to quantify the associations of two separate proteins and their common target DNA. STAR Protocols 2, 100504.
9. Gao, J.*, He, L.*, Shi, Y., Cai, M., Xu, H., Jiang, J., Zhang, L., and Wang, H. (2017). Cell contact and pressure control of YAP localization and clustering revealed by super-resolution imaging. Nanoscale 9, 16993-17003.
10. Fan, X.*, He, L.*, Meng, Y., Li, G., Li, L., and Meng, Y. (2015). Alpha-MMC and MAP30, two ribosome-inactivating proteins extracted from Momordica charantia, induce cell cycle arrest and apoptosis in A549 human lung carcinoma cells. Mol Med Rep 11, 3553-3558.
11. Gao, J., He, L., Zhou, L., Jing, Y., Wang, F., et al. and Wang, H. (2020). Mechanical force regulation of YAP by F-actin and GPCR revealed by super-resolution imaging. Nanoscale 12, 2703-2714.
12. Feng, X., Lu, T., Li, J., Yang, R., Hu, L., Ye, Y., Mao, F., He, L., et al., and Zhang L. (2020). The Tumor Suppressor Interferon Regulatory Factor 2 Binding Protein 2 Regulates Hippo Pathway in Liver Cancer by a Feedback Loop in Mice. Hepatology 71, 1988-2004.
13. Feng, X., Wang, Z., Wang, F., Lu, T., Xu, J., Ma, X., Li, J., He, L., et al. and Zhang L. (2019). Dual function of VGLL4 in muscle regeneration. EMBO J 38, e101051.
14. Zhang, W., Xu, J., Li, J., Guo, T., Jiang, D., Feng, X., Ma, X., He, L., et al. and Zhang L. (2018). The TEA domain family transcription factor TEAD4 represses murine adipogenesis by recruiting the cofactors VGLL4 and CtBP2 into a transcriptional complex. J Biol Chem 293, 17119-17134.
团队介绍
欢迎感兴趣的有志青年加入！
